Grupo de Investigación en Reumatología y Salud
GIR-S
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (5)
2023
-
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
Journal of Rheumatology, Vol. 50, Núm. 4, pp. 478-487
2022
2021
-
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539
2020
-
Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810
2014
-
Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies
Arthritis and Rheumatology, Vol. 66, Núm. 4, pp. 940-949